View Older Stories View More Recent Stories

Jul 27, 2023 07:00AM Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Jun 16, 2023 04:08PM Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2023 01:00PM Optinose to Present at the Jefferies Healthcare Conference
May 11, 2023 07:00AM Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 4, 2023 07:24AM OptiNose (OPTN) Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 4, 2023 07:00AM Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 1, 2023 04:30PM Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Apr 18, 2023 08:00AM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 12, 2023 04:00PM Optinose to Present at the Needham Virtual Healthcare Conference
Mar 7, 2023 07:00AM Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Feb 28, 2023 04:30PM Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Feb 21, 2023 07:08AM OptiNose (OPTN) Submits Supplemental New Drug Application for XHANCE Label Expansion
Feb 21, 2023 07:00AM Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
Jan 31, 2023 07:00AM Optinose Announces CEO Transition and Business Update
Dec 15, 2022 04:30PM OptiNose (OPTN) Appoints Paul Spence as Chief Commercial Officer
Dec 15, 2022 04:30PM Optinose Appoints Paul Spence as Chief Commercial Officer
Dec 9, 2022 08:02AM OptiNose (OPTN) Announces Departure of Acting Chief Financial Officer
Dec 9, 2022 08:00AM Optinose Announces Departure of Acting Chief Financial Officer
Nov 30, 2022 07:00AM Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
Nov 10, 2022 07:00AM Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
Nov 9, 2022 03:00PM Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
Nov 7, 2022 03:00PM Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Oct 21, 2022 07:00AM Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Sep 6, 2022 12:00PM Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
Aug 11, 2022 07:00AM Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Aug 8, 2022 04:20PM Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Jul 13, 2022 07:00AM Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
Jul 8, 2022 07:00AM OptiNose (OPTN) Reports Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Jul 8, 2022 07:00AM Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Jun 13, 2022 07:02AM OptiNose (OPTN) Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Jun 13, 2022 07:00AM Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Jun 3, 2022 07:02AM OptiNose (OPTN) Announces CFO Departure
Jun 3, 2022 07:00AM Optinose Announces Departure of Chief Financial Officer
May 12, 2022 07:00AM Optinose Reports First Quarter 2022 Financial Results and Operational Updates
May 5, 2022 05:00PM Optinose Announces Reporting Date for First Quarter 2022 Financial Results
Apr 26, 2022 08:06AM OptiNose (OPTN) Appoints R. John Fletcher to its Board
Apr 26, 2022 08:00AM Optinose Announces Appointment of R. John Fletcher to the Board
Apr 8, 2022 08:30AM Optinose to Present at the Needham Virtual Healthcare Conference
Mar 8, 2022 07:00AM Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Mar 7, 2022 07:00AM Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
Mar 4, 2022 02:00PM Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
Dec 13, 2021 07:56AM OptiNose (OPTN) Appoints Eric Bednarski and Kyle Dempsey to its Board
Dec 13, 2021 07:54AM Optinose Announces Appointment of Two New Members to Board of Directors
Nov 23, 2021 07:00AM Optinose to Present at the Piper Sandler Virtual Healthcare Conference
Nov 18, 2021 04:30PM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 15, 2021 04:26PM Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
Nov 10, 2021 05:50PM Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
Oct 28, 2021 06:59AM Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
Sep 22, 2021 04:15PM Optinose to Present at the Cantor Virtual Global Healthcare Conference
Aug 25, 2021 05:00PM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories